ArcherDX Blog



Aug
29
2018

New features in Archer Analysis 6.0

Archer Analysis has been updated to version 6.0, making it more powerful and versatile than ever.


Aug
1
2018

High coverage and noise characterization of CEBPA for sensitive and specific variant detection

CEBPA mutations are important prognostic indicators in AML, however detecting CEBPA mutations by NGS is challenging due to high GC content. Here, we show that AMP-based NGS provides superior coverage of CEBPA and we demonstrate the use of normalization datasets to assess the noise at each base position to calculate the per-base variant detection sensitivity across CEBPA, expressed as 95 MDAF.


Apr
12
2018

Press release: Washington University, ArcherDX partner for MRD in pediatric AML sequencing study

Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).


Apr
4
2018

Cancer and ALK, RET, ROS1 gene fusions

Cancer is caused by mutations in specific genes. Many of these genes, including ALK, RET and ROS1, are called driver oncogenes because they are critical to the survival, growth and proliferation of cancer cells


Mar
30
2018

2018 Calendar of Events

Where in the world is ArcherDX? Archer will be traveling to multiple conferences around the world again this year. We hope to see you!


Mar
30
2018

Archer announces the 2018 Research Challenge Grant Winners

Archer awards 5 recipients up to 96 free reactions (12 kits with 8 reactions each) of an Archer Assay in the fields of mutation tracking, liquid biopsy and immune repertoire.


Mar
26
2018

Press release: ArcherDX and Ambry Genetics to provide immune repertoire and CAR-T- related sequencing services

ArcherDX and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX’s next-generation sequencing (NGS) assays.


Mar
20
2018

Full BRCA coverage to detect pathogenic variants by NGS

Full BRCA coverage to detect pathogenic variants by NGS


Mar
20
2018

Press release: ArcherDX Closes $35 Million Series A Financing

ArcherDX, Inc. announces that it has closed a $35 million Series A Preferred financing.


Feb
26
2018

NGS assays that match the pace of discovery

The modularity of Archer’s AMP chemistry allows users to create personalized NGS panels with the utmost flexibility and confidence. With coverage, panel uniformity and on-target reads at >90%, your custom assay is guaranteed to work for your applications. Additionally, any Archer assay is future-proof. When your team decides upon an updated list of key gene targets, simply add gene targets to an existing panel, or create an entirely new custom panel, without sacrificing performance.

How to contact us

Address

2477 55th Street, Suite 202

Boulder, CO 80301

Phone

Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.